Oral Administration of Ethanolamine Glycerophospholipid Containing a High Level of Plasmalogen Improves Memory Impairment in Amyloid β‐Infused Rats
Authors:
Abstract
Ethanolamine plasmalogen (PlsEtn), a major phospholipid in neuronal membranes [60–90 mol% of ethanolamine glycerophospholipid (EtnGpl)], is specifically decreased in brains from patients with Alzheimer's disease (AD). The present study investigated how PlsEtn administration affects cognitive deficits and lipid composition in an animal model of AD. AD model rats were infused with amyloid‐β (Aβ) into the cerebral ventricle and divided into three groups. Control, Egg, and Ascidian groups were then orally administered vehicle, egg yolk EtnGpl (260 μmol as EtnGpl/kg BW/day; 10 μmol as PlsEtn/kg BW/day), or ascidian viscera EtnGpl (260 μmol as EtnGpl/kg BW/day; 209 μmol as PlsEtn/kg BW/day), respectively. After 4 weeks of dosing, Aβ‐infused rats were tested for learning ability in an 8‐arm radial maze. The administration of ascidian viscera EtnGpl improved both reference and working memory‐related learning abilities. In lipid analysis, the Ascidian group showed higher levels of PlsEtn species in the plasma, erythrocytes, and liver when compared to other groups. In addition, although there were no differences at levels of total plasmalogen including choline plasmalogen, the Ascidian group had significantly higher levels of 18:0ol/22:6‐PlsEtn in the cerebral cortex. These levels of 18:0ol/22:6‐PlsEtn in the cerebral cortex were correlated with working memory‐related learning ability. Moreover, 18:0ol/22:6‐PlsEtn levels in the cerebral cortex showed positive correlations with those in the erythrocytes and liver. In summary, dietary PlsEtn, especially that with 22:6n‐3 (docosahexaenoic acid, DHA), may ameliorate learning deficiencies in AD by altering lipid composition in the brain.Keywords
This publication has 53 references indexed in Scilit:
- Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systemsFree Radical Biology and Medicine, 2011
- Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's diseaseLipids in Health and Disease, 2011
- 1,2-Dilinoleoyl-sn-glycero-3-phosphoethanolamine ameliorates age-related spatial memory deterioration by preventing neuronal cell deathBehavioral and Brain Functions, 2010
- Membrane rafts in Alzheimer's disease beta-amyloid productionBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Docosahexaenoic acid neurolipidomicsProstaglandins & Other Lipid Mediators, 2010
- Quantitative contributions of diet and liver synthesis to docosahexaenoic acid homeostasisProstaglandins, Leukotrienes and Essential Fatty Acids, 2010
- Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's diseaseNature Neuroscience, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995